Sirolimus-eluting Stents Versus Paclitaxel-eluting Stents In Diabetic Patients With Coronary Artery Disease-a Meta-analysis Of Randomized Controlled Trials

Objective To assess the efficacy and safety of sirolimus-eluting stent (SES) andpaclitaxel-eluting stent (PES) in Diabetic Patients with Coronary Artery Disease.Methods Retrieved clinical trials were searched from Pubmed,Cochrane librarycontrolled trials center registration database,Wangfang database,Vip database,Chinesebiomedical literature database up to July2012without limit of language.Identify studieson SES versus PES in Diabetic Patients with Coronary Artery Disease. Methodologicalquality of the study was assessed based on Cochrance Reviewers’ Handbook andJadad’sScore Scale.Statistical software RevMan5.1was used for Meta-analysis.Assessand compare the target Lesion Revascularization(TLR),Target VesselRevascularization(TVR) and stent thrombosis,cardiac death,myocardial infarctionbetween SES and PES.Results No significant heterogeneity was seen across the8randomized trials for allanalyzed events. Sirolimus-eluting stent was associated with a significant reduction inthe risk of TLR（OR:0.53，95%CI:0.38～0.74，P=0.0002）and TVR（OR:0.70，95%CI:0.50～0.98，P=0.04）. No significant differences were observed regarding therisk of death（OR:0.95，95%CI:0.59～1.54，P=0.84）, myocardial infarction（OR：0.79，95%CI:0.46～1.38，P=0.41）and stent thrombosis（OR:0.91，95%CI:0.46～1.82，P=0.79）.Conclusions In diabetic patients with coronary artery disease，SES leads a reductionin the risk of TLR and TVR compared with PES.But there is no differences in the risk of stent thrombosis,death and myocardial infarction.